Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies-Reference-Cited by-同舟云学术

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

Published:2016-07-25 Issue:12 Volume:19 Page:1216-1225
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Fleischmann Roy¹,Kremer Joel²,Tanaka Yoshiya³,Gruben David⁴,Kanik Keith⁴,Koncz Tamas⁵,Krishnaswami Sriram⁴,Wallenstein Gene⁴,Wilkinson Bethanie⁴,Zwillich Samuel H.⁴,Keystone Edward⁶

Affiliation:

1. Metroplex Clinical Research Center; Dallas Texas USA

2. Center for Rheumatology; Albany Medical College; Albany New York USA

3. First Department of Internal Medicine; School of Medicine; University of Occupational and Environmental Health; Kitakyushu Japan

4. Pfizer Inc.; Groton Connecticut USA

5. Pfizer Inc.; New York New York USA

6. Mount Sinai Hospital; Toronto Ontario Canada

Funder

Pfizer

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.12901/fullpdf

Reference33 articles.

1. The impact of rheumatoid arthritis and treatment on patients’ lives;Strand;Clin Exp Rheumatol,2010

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs;Smolen;Ann Rheum Dis,2010

3. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial;Rezaei;Ann Rheum Dis,2012

4. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

5. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy;Barton;Patient Prefer Adherence,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil-lymphocyte ratio: an independent predictor of the herpes zoster risk in rheumatoid arthritis patients treated with tofacitinib;Aktuelle Rheumatologie;2024-02-19

2. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis;Expert Review of Clinical Immunology;2024-02-08

3. Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate;Arthritis & Rheumatology;2020-09-07

4. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future;Biomolecules;2020-07-05

5. Preclinical ex-vivo Testing of Anti-inflammatory Drugs in a Bovine Intervertebral Degenerative Disc Model;Frontiers in Bioengineering and Biotechnology;2020-06-10